FUT4 promotes the progression of Cholangiocarcinoma by modulating epithelial-mesenchymal transition

References

• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179. doi: 10.1016/S0140-6736(13)61903-0
   PubMed Web of Science ®Google Scholar
• Ruiz de Gauna M, Biancaniello F, González-Romero F, et al. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology. 2022;76(6):1617–1633. doi: 10.1002/hep.32344
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. doi: 10.1038/nrclinonc.2017.157
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–555. doi: 10.1038/nrc3982
   PubMed Web of Science ®Google Scholar
• Aziz F, Gao W, Yan Q. Fucosyltransferase-4 and Oligosaccharide Lewis Y antigen as potentially correlative biomarkers of Helicobacter pylori CagA associated gastric cancer. Pathol Oncol Res. 2017;23(1):173–179. doi: 10.1007/s12253-016-0122-1
   PubMed Web of Science ®Google Scholar
• Zheng Q, Cui X, Zhang D, et al. miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and α1,3-fucosylated glycans. Oncogenesis. 2017;6(7):e358. doi: 10.1038/oncsis.2017.58
   PubMedGoogle Scholar
• Lv Y, Zhang Z, Tian S, et al. Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors. Drug Discov Today. 2023;28(1):103394. doi: 10.1016/j.drudis.2022.103394
   PubMed Web of Science ®Google Scholar
• Hatakeyama S, Yoneyama T, Tobisawa Y, et al. Recent progress and perspectives on prostate cancer biomarkers. Int J Clin Oncol. 2017;22(2):214–221. doi: 10.1007/s10147-016-1049-y
   PubMed Web of Science ®Google Scholar
• Saldova R, Struwe WB, Wynne K, et al. Exploring the glycosylation of serum CA125. Int J Mol Sci. 2013;14(8):15636–15654. doi: 10.3390/ijms140815636
   PubMed Web of Science ®Google Scholar
• Scarà S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247–260. doi: 10.1007/978-94-017-7215-0_15
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee SW. The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. Gastroenterol Res Pract. 2017;2017:7521987. doi: 10.1155/2017/7521987
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi: 10.1038/s41580-018-0080-4
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016. Cell. 2016;166(1):21–45. doi: 10.1016/j.cell.2016.06.028
   PubMed Web of Science ®Google Scholar
• Tian L, Shen D, Li X, et al. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget. 2016;7(2):1619–1632. doi: 10.18632/oncotarget.6451
   PubMedGoogle Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Blighe K, Rana S, Lewis M. 2018. EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling. https://github.com/kevinblighe/EnhancedVolcano.
   Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi: 10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Pinho SS, Seruca R, Gärtner F, et al. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell Mol Life Sci. 2011;68(6):1011–1020. doi: 10.1007/s00018-010-0595-0
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdóttir H, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi: 10.1016/j.cels.2015.12.004
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi: 10.1038/nrm3758
   PubMed Web of Science ®Google Scholar
• Eckert MA, Lwin TM, Chang AT, et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011;19(3):372–386. doi: 10.1016/j.ccr.2011.01.036
   PubMed Web of Science ®Google Scholar
• Fenouille N, Tichet M, Dufies M, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PloS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378
   PubMed Web of Science ®Google Scholar
• Blanas A, Sahasrabudhe NM, Rodríguez E, et al. Fucosylated antigens in cancer: an alliance toward tumor progression, metastasis, and resistance to chemotherapy. Front Oncol. 2018;8:39. doi: 10.3389/fonc.2018.00039
   PubMed Web of Science ®Google Scholar
• Lu HH, Lin SY, Weng RR, et al. Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma. EBioMedicine. 2020;57:102846. doi: 10.1016/j.ebiom.2020.102846
   PubMed Web of Science ®Google Scholar
• Hirakawa M, Takimoto R, Tamura F, et al. Fucosylated TGF-β receptors transduces a signal for epithelial–mesenchymal transition in colorectal cancer cells. Br J Cancer. 2014;110(1):156–163. doi: 10.1038/bjc.2013.699
   PubMed Web of Science ®Google Scholar
• Li Y, Sun Z, Liu B, et al. Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. Cell Death Dis. 2017;8(6):e2892. doi: 10.1038/cddis.2017.281
   PubMedGoogle Scholar
• Liang L, Gao C, Li Y, et al. miR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway. Cell Death Dis. 2017;8(8):e2968. doi: 10.1038/cddis.2017.352
   PubMedGoogle Scholar
• Madjd Z, Parsons T, Watson NF, et al. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res. 2005;7(5):R780–787. doi: 10.1186/bcr1305
   PubMed Web of Science ®Google Scholar
• Koh YW, Lee HJ, Ahn JH, et al. Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer. Am J Clin Pathol. 2013;139(6):746–753. doi: 10.1309/AJCP2E6QNDIDPTTC
   PubMed Web of Science ®Google Scholar
• Kadota A, Masutani M, Takei M, et al. Evaluation of expression of CD15 and sCD15 in non-small cell lung cancer. Int J Oncol. 1999;15:1081–1089. doi: 10.3892/ijo.15.6.1081
   PubMed Web of Science ®Google Scholar
• Tanaka F, Miyahara R, Ohtake Y, et al. Lewis Y antigen expression and postoperative survival in non–small cell lung cancer. Annals Thorac Surg. 1998;66(5):1745–1750. doi: 10.1016/s0003-4975(98)00937-0
   PubMed Web of Science ®Google Scholar
• Wang QY, Wu SL, Chen JH, et al. Expressions of Lewis antigens in human non-small cell pulmonary cancer and primary liver cancer with different pathological conditions. J Exp Clin Cancer Res. 2003;22(3):431–440.
   PubMed Web of Science ®Google Scholar
• Gilgunn S, Conroy PJ, Saldova R, et al. Aberrant PSA glycosylation—a sweet predictor of prostate cancer. Nat Rev Urol. 2013;10(2):99–107. doi: 10.1038/nrurol.2012.258
   PubMed Web of Science ®Google Scholar
• Ball ED, Schwarz LM, Bloomfield CD. Expression of the CD15 antigen on normal and leukemic myeloid cells: effects of neuraminidase and variable detection with a panel of monoclonal antibodies. Mol Immunol. 1991;28(9):951–958. doi: 10.1016/0161-5890(91)90180-r
   PubMed Web of Science ®Google Scholar
• Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99(9):1375–1379. doi: 10.1038/sj.bjc.6604662
   PubMed Web of Science ®Google Scholar
• Yan L, Lin B, Gao L, et al. Lewis (y) antigen overexpression increases the expression of MMP-2 and MMP-9 and invasion of human ovarian cancer cells. IJMS. 2010;11(11):4441–4452. doi: 10.3390/ijms11114441
   Google Scholar
• Yang X, Liu S, Yan Q. Role of fucosyltransferase IV in epithelial–mesenchymal transition in breast cancer cells. Cell Death Dis. 2013;4(7):e735. doi: 10.1038/cddis.2013.241
   PubMedGoogle Scholar
• Huang C, Zhan T, Liu Y, et al. Glycomic profiling of carcinoembryonic antigen isolated from human tumor tissue. Clin Proteomics. 2015;12(1):17. doi: 10.1186/s12014-015-9088-3
   PubMedGoogle Scholar
• Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–182. doi: 10.1038/nature14581
   PubMed Web of Science ®Google Scholar
• Pedersen JW, Gentry-Maharaj A, Nøstdal A, et al. Cancer-associated autoantibodies to MUC1 and MUC4—A blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer. 2014;134(9):2180–2188. doi: 10.1002/ijc.28538
   PubMed Web of Science ®Google Scholar
• Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta. 2012;1820(9):1347–1353. doi: 10.1016/j.bbagen.2011.12.001
   PubMed Web of Science ®Google Scholar